MX2023012793A - Métodos y composiciones para el tratamiento de la retinopatía diabética y condiciones relacionadas. - Google Patents

Métodos y composiciones para el tratamiento de la retinopatía diabética y condiciones relacionadas.

Info

Publication number
MX2023012793A
MX2023012793A MX2023012793A MX2023012793A MX2023012793A MX 2023012793 A MX2023012793 A MX 2023012793A MX 2023012793 A MX2023012793 A MX 2023012793A MX 2023012793 A MX2023012793 A MX 2023012793A MX 2023012793 A MX2023012793 A MX 2023012793A
Authority
MX
Mexico
Prior art keywords
compositions
diabetic retinopathy
methods
treatment
related conditions
Prior art date
Application number
MX2023012793A
Other languages
English (en)
Spanish (es)
Inventor
Mark R Kelley
Mina Sooch
Konstantinos Charizanis
Richard Adam Messmann
Mitchell George Brigell
Ronil Ajaykumar Patel
Original Assignee
Ocuphire Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocuphire Pharma Inc filed Critical Ocuphire Pharma Inc
Publication of MX2023012793A publication Critical patent/MX2023012793A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023012793A 2021-04-30 2022-04-29 Métodos y composiciones para el tratamiento de la retinopatía diabética y condiciones relacionadas. MX2023012793A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163182037P 2021-04-30 2021-04-30
PCT/US2022/027062 WO2022232597A1 (en) 2021-04-30 2022-04-29 Methods and compositions for treatment of diabetic retinopathy and related conditions

Publications (1)

Publication Number Publication Date
MX2023012793A true MX2023012793A (es) 2024-01-11

Family

ID=83848745

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012793A MX2023012793A (es) 2021-04-30 2022-04-29 Métodos y composiciones para el tratamiento de la retinopatía diabética y condiciones relacionadas.

Country Status (11)

Country Link
US (1) US20240216315A1 (enExample)
EP (1) EP4329741A4 (enExample)
JP (1) JP2024516003A (enExample)
KR (1) KR20240049212A (enExample)
CN (1) CN117500492A (enExample)
AU (1) AU2022264037A1 (enExample)
BR (1) BR112023022561A2 (enExample)
CA (1) CA3217136A1 (enExample)
IL (1) IL308083A (enExample)
MX (1) MX2023012793A (enExample)
WO (1) WO2022232597A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4587003A2 (en) 2022-09-14 2025-07-23 Opus Genetics, Inc. Salts and esters of apx3330 and therapeutic uses thereof
WO2024158972A1 (en) * 2023-01-25 2024-08-02 Ocuphire Pharma, Inc. Methods and compositions for preventing the progression of diabetic retinopathy and related conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008304619C1 (en) * 2007-09-26 2020-06-04 Indiana University Research And Technology Corporation Benzoquinone derivative E3330 in combination with chemotherapeutic agents for the treatment of cancer and angiogenesis
AU2019218797B2 (en) * 2018-02-08 2023-09-21 Indiana University Research And Technology Corporation Targeting ocular diseases with novel APE1/Ref-1 inhibitors

Also Published As

Publication number Publication date
BR112023022561A2 (pt) 2024-01-02
US20240216315A1 (en) 2024-07-04
CA3217136A1 (en) 2022-11-03
JP2024516003A (ja) 2024-04-11
CN117500492A (zh) 2024-02-02
IL308083A (en) 2023-12-01
AU2022264037A1 (en) 2023-11-16
EP4329741A4 (en) 2025-01-08
EP4329741A1 (en) 2024-03-06
WO2022232597A1 (en) 2022-11-03
KR20240049212A (ko) 2024-04-16

Similar Documents

Publication Publication Date Title
De Keyser et al. Selective laser trabeculoplasty as replacement therapy in medically controlled glaucoma patients
EP4491229A3 (en) Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
MX2020003534A (es) Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
MX2023012793A (es) Métodos y composiciones para el tratamiento de la retinopatía diabética y condiciones relacionadas.
BR112016015763B8 (pt) preparação farmacêutica incluindo composto de ácido piridilaminocético, e, uso da mesma
BRPI0408690A (pt) composto, método para tratamento de uma doença, composição farmacêutica, e, uso de um composto
MX2020009132A (es) Composiciones farmaceuticas que comprenden nebivolol.
CL2021003312A1 (es) Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.
ECSP22086300A (es) Composiciones que comprenden nanopartículas, método de elaboración y usos de las mismas
BR112021017436A2 (pt) Composições farmacêuticas para tratamento de doenças ou transtornos oculares
MX2022011697A (es) Inhibidores de ciclofilina y usos de los mismos.
MX2019013799A (es) Peptido novedoso y composicion farmaceutica para tratar una enfermedad ocular que comprende el mismo como un ingrediente farmaceutico activo.
JOP20230133A1 (ar) استخدام منشطات sGC لمعالجة الأمراض العينية
PH12020551015A1 (en) Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability
AU2017261303A1 (en) Ophthalmic compositions
BR112023018932A2 (pt) Formulação para administração ocular, recipiente de dosagem, uso de uma formulação, e, método para o tratamento de um transtorno ocular
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
CO2025015464A2 (es) Implante ocular que comprende el polimorfo iv de axitinib
WO2023147513A3 (en) Compositions of autophagy modulating agents and uses thereof
MX2023010918A (es) Metodos y composiciones para el tratamiento de enfermedades oculares.
RU95104837A (ru) Способ хирургического лечения отслойки сетчатки, осложненной пролиферативной витреоретинопатией
BR0307013A (pt) Usos farmacêuticos
EA202000298A1 (ru) ПРОТИВОКОРОНАВИРУСНОЕ СРЕДСТВО ДЛЯ КОМБИНИРОВАННОЙ ТЕРАПИИ COVID-19 (SARS-CoV-2) И СПОСОБ ЛЕЧЕНИЯ
EA202000299A1 (ru) ПРОТИВОКОРОНАВИРУСНОЕ СРЕДСТВО ДЛЯ КОМБИНИРОВАННОЙ ТЕРАПИИ COVID-19 (SARS-CoV-2)
EA202091523A1 (ru) Терапевтический агент для лечения глаукомы, содержащий агонист fp-рецепторов и -блокатор